ArticleJournal of inflammation research2025
Xijiao Dihuang Decoction for Sepsis-Induced Acute Lung Injury: Network Pharmacology and Molecular Dynamics Insights.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rehmanniae Radix Powder Enhances Antioxidative Capacity, Immunity, and Gut Health in Late-Phase Laying Hens.Animals : an open access journal from MDPI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigates the therapeutic mechanisms of Xijiao Dihuang Decoction (XJDHD) in sepsis-induced acute lung injury (SALI) through an integrated approach, including network pharmacology, molecular docking, molecular dynamics simulations, and in vitro experiments. Methods: Network pharmacology identified active ingredients and targets in Xijiao Dihuang Decoction. Molecular docking and dynamics simulations evaluated binding affinity and stability with key targets. In vitro experiments on LPS-stimulated A549 cells substantiated Xijiao Dihuang Decoction's anti-inflammatory, antioxidant, and anti-apoptotic effects. Results: Network pharmacology identified 20 active components among 182 Sepsis-Induced Acute Lung Injury targets. Molecular docking revealed strong binding affinity (binding energies ≤ -5.0 kcal/mol) for β-sitosterol with AKT1 and TNF. Molecular dynamics confirmed the complex stability. In vitro experiments demonstrated that Xijiao Dihuang Decoction significantly reduced inflammatory cytokines IL-6, TNF-α, and IL-1β ( Conclusion: Xijiao Dihuang Decoction exhibits therapeutic efficacy in treating Sepsis-Induced Acute Lung Injury through its anti-inflammatory, antioxidant, and anti-apoptotic effects, and by modulating the PI3K/Akt pathway. This study provides experimental evidence for Xijiao Dihuang Decoction's mechanisms, highlighting its potential. However, additional in vivo and clinical investigations are required to validate its efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.